Stockreport
Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026
Last allogene therapeutics, inc. earnings: 2/27 04:30 am
Check Earnings Report
SOUTH SAN FRANCISCO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products, today announced upcoming presentations at the American Association for Cancer Research (AACR) Annual Meeting, April 17-22, 2026, in San Diego, Calif. Allogene’s presentations at AACR highlight the potential of allogeneic CAR T to expand access, simplify delivery, and enable broader application of cell therapy across diseases when its inherent advantages are fully leveraged. The Company will participate in several AACR 2026 scientific forums, including: Poster: Preclinical Evaluation of Allogeneic BCMA/CD70 Dual CAR T Cells for High-Risk Multiple MyelomaPresenter: Mark K. O’Dair, PhD, AllogeneSession Title: CAR T Cell Targets and TME ReprogrammingPoster Number: 1535Location: Poster Section 7, Board 17Session Date and Time: Monday, April 20, 9:00am-12:00pm PT Based on i
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | ALLO | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
ALLO alerts
ALLO alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALLO alerts
High impacting Allogene Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ALLO
NEWS
NEWS
- Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock[GlobeNewswire]
- Allogene Therapeutics (ALLO) was upgraded by JPMorgan Chase & Co. from "underweight" to "neutral".[MarketBeat]
- Allogene Therapeutics (ALLO) Is Down 13.0% After $175M Equity Raise On ALPHA3 MRD Data Release – Has The Bull Case Changed? [Yahoo! Finance][Yahoo! Finance]
- Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases[GlobeNewswire]
- Allogene Therapeutics Announces Pricing of Public Offering of Common Stock[GlobeNewswire]
- More
ALLO
SEC Filings
SEC Filings
- 4/20/26 - Form PRE
- 4/15/26 - Form 8-K
- 4/15/26 - Form 424B5
- ALLO's page on the SEC website
- More